Chemistry:AMG319
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H16FN7 |
| Molar mass | 385.396 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AMG319 is a drug developed by Amgen which acts as an inhibitor of the phosphoinositide 3-kinase enzyme subtype PI3Kδ. It was originally developed as an anti-inflammatory drug with potential applications in the treatment of autoimmune conditions such as rheumatoid arthritis, but subsequent research showed that it inhibits cell proliferation and might potentially have useful anti-cancer effects, and it has been put into clinical trials to assess its safety and tolerability in this application.[1][2]
Mechanism(s) of action
It is a potential immunotherapy because blocking PI3Kδ (PI3K p110δ) eliminates a group of inhibitory immune cells and may allow the immune system to better attack the cancer cells.[3] p110δ inactivation in regulatory T cells unleashes CD8+ cytotoxic T cells.[4]
Clinical trials
Its first clinical trial was a phase I/II study in adults with relapsed or refractory lymphoid malignancies.[5] This was due to run from 2011 to 2013.
In 2015/16 it started a phase II clinical trial as a neoadjuvant therapy for human papillomavirus (HPV) negative head and neck squamous-cell carcinoma (HNSCC) (prior to resection surgery).[3]
See also
References
- ↑ Cushing, TD; Hao, X; Shin, Y; Andrews, K; Brown, M; Cardozo, M; Chen, Y; Duquette, J et al. (8 January 2015). "Discovery and In Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease". Journal of Medicinal Chemistry 58 (1): 480–511. doi:10.1021/jm501624r. PMID 25469863.
- ↑ Lanasa MC, Glenn MJ, Mato AR, Allgood SD, Wong S, Amore B, Means GD, Stevens E, Yan C, Friberg G, Goy A. First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies. 55th ASH Annual Meeting and Exposition, December 2013
- ↑ 3.0 3.1 AMG 319 in Human PapillomaVirus (HPV) Negative HNSCC
- ↑ Ali, Khaled; Soond, Dalya R.; Piñeiro, Roberto; Hagemann, Thorsten; Pearce, Wayne; Lim, Ee Lyn; Bouabe, Hicham; Scudamore, Cheryl L. et al. (2014). "Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer". Nature 510 (7505): 407–11. doi:10.1038/nature13444. PMID 24919154.
- ↑ A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
 |
